Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target

Edward P. Retzbach, Stephanie A. Sheehan, Evan M. Nevel, Amber Batra, Tran Phi, Angels T.P. Nguyen, Yukinari Kato, Soly Baredes, Mahnaz Fatahzadeh, Alan J. Shienbaum, Gary S. Goldberg

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Oral cancer has become one of the most aggressive types of cancer, killing 140,000 people worldwide every year. Current treatments for oral cancer include surgery and radiation therapies. These procedures can be very effective; however, they can also drastically decrease the quality of life for survivors. New chemotherapeutic treatments are needed to more effectively combat oral cancer. The transmembrane receptor podoplanin (PDPN) has emerged as a functionally relevant oral cancer biomarker and chemotherapeutic target. PDPN expression promotes tumor cell migration leading to oral cancer invasion and metastasis. Here, we describe the role of PDPN in oral squamous cell carcinoma progression, and how it may be exploited to prevent and treat oral cancer.

Original languageEnglish (US)
Pages (from-to)126-136
Number of pages11
JournalOral Oncology
Volume78
DOIs
StatePublished - Mar 1 2018

All Science Journal Classification (ASJC) codes

  • Oral Surgery
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target'. Together they form a unique fingerprint.

Cite this